HK1218251A1 - 用拉喹莫德治療多發性硬化症 - Google Patents

用拉喹莫德治療多發性硬化症

Info

Publication number
HK1218251A1
HK1218251A1 HK16106220.1A HK16106220A HK1218251A1 HK 1218251 A1 HK1218251 A1 HK 1218251A1 HK 16106220 A HK16106220 A HK 16106220A HK 1218251 A1 HK1218251 A1 HK 1218251A1
Authority
HK
Hong Kong
Prior art keywords
laquinimod
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
HK16106220.1A
Other languages
English (en)
Inventor
Tarcic Nora
Bar-Zohar Dan
Hayardeny Liat
Gilgun Sherki Yossi
Gorfine Tali
Knappertz Volker
Sorani Ella
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1218251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1218251A1 publication Critical patent/HK1218251A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
HK16106220.1A 2013-02-15 2016-06-01 用拉喹莫德治療多發性硬化症 HK1218251A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US201361911106P 2013-12-03 2013-12-03
PCT/US2014/016278 WO2014127139A1 (en) 2013-02-15 2014-02-13 Treatment of multiple sclerosis with laquinimod

Publications (1)

Publication Number Publication Date
HK1218251A1 true HK1218251A1 (zh) 2017-02-10

Family

ID=51351655

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16106220.1A HK1218251A1 (zh) 2013-02-15 2016-06-01 用拉喹莫德治療多發性硬化症
HK16106269.3A HK1218254A1 (zh) 2013-02-15 2016-06-02 用拉喹莫德治療多發性硬化症

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16106269.3A HK1218254A1 (zh) 2013-02-15 2016-06-02 用拉喹莫德治療多發性硬化症

Country Status (18)

Country Link
US (2) US20140235670A1 (zh)
EP (1) EP2956137A4 (zh)
JP (1) JP2016510343A (zh)
KR (1) KR20150119227A (zh)
CN (1) CN105163737A (zh)
AU (1) AU2014216199A1 (zh)
BR (1) BR112015019564A2 (zh)
CA (1) CA2900503A1 (zh)
CL (1) CL2015002181A1 (zh)
EA (1) EA201591507A1 (zh)
HK (2) HK1218251A1 (zh)
IL (1) IL240014A0 (zh)
MX (1) MX2015010296A (zh)
PE (1) PE20151526A1 (zh)
SG (1) SG11201505818WA (zh)
TW (1) TW201442709A (zh)
UY (1) UY35328A (zh)
WO (1) WO2014127139A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
MX2016013944A (es) * 2014-04-29 2017-01-09 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis multiple recidivante-remitente (rrms) con un alto estado de discapacidad.
EP3206682B1 (en) * 2014-10-16 2018-09-26 Novartis AG Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
CN110382052A (zh) * 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
EP2035001B1 (en) * 2006-06-12 2011-11-09 Teva Pharmaceutical Industries Limited Stable laquinimod preparations
US8138201B2 (en) * 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
CA2747235C (en) * 2008-12-11 2021-02-09 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
MX2011013902A (es) * 2009-06-19 2012-02-23 Teva Pharma Tratamiento de esclerosis multiple con laquinimod.
WO2012078591A1 (en) * 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
CN103781355A (zh) * 2011-07-28 2014-05-07 泰华制药工业有限公司 用拉喹莫德与干扰素-β的组合治疗多发性硬化症
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
WO2014058979A2 (en) * 2012-10-12 2014-04-17 Teva Pharmaceuticals Usa, Inc. Laquinimod for reducing thalamic damage in multiple sclerosis
MX2016013944A (es) * 2014-04-29 2017-01-09 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis multiple recidivante-remitente (rrms) con un alto estado de discapacidad.

Also Published As

Publication number Publication date
US20140235670A1 (en) 2014-08-21
EP2956137A4 (en) 2016-08-03
KR20150119227A (ko) 2015-10-23
EA201591507A1 (ru) 2015-12-30
CN105163737A (zh) 2015-12-16
US20180064702A1 (en) 2018-03-08
AU2014216199A1 (en) 2015-09-03
HK1218254A1 (zh) 2017-02-10
JP2016510343A (ja) 2016-04-07
SG11201505818WA (en) 2015-08-28
WO2014127139A1 (en) 2014-08-21
PE20151526A1 (es) 2015-11-20
TW201442709A (zh) 2014-11-16
UY35328A (es) 2014-09-30
CA2900503A1 (en) 2014-08-21
IL240014A0 (en) 2015-09-24
EP2956137A1 (en) 2015-12-23
BR112015019564A2 (pt) 2017-07-18
MX2015010296A (es) 2016-05-05
CL2015002181A1 (es) 2016-06-03

Similar Documents

Publication Publication Date Title
HRP20181296T1 (hr) Novi spojevi za suzbijanje člankonožaca
IL252547A0 (en) Treatment of multiple sclerosis using laquinimod
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
HK1213818A1 (zh) 依帕列淨的治療用途
RS58097B1 (sr) Terapeutske primene empagliflozina
HK1218254A1 (zh) 用拉喹莫德治療多發性硬化症
IL241096B (en) Treatment methods
HK1223855A1 (zh) 拉喹莫德和氟吡汀組合物用於治療多發性硬化症
HK1225971A1 (zh) 使用拉喹莫德治療青光眼
IL244620A0 (en) A drug combination including laquinimod for the treatment of multiple sclerosis
ZA201601626B (en) Treatment of gases
HK1227691A1 (zh) 利用拉喹莫德和特立氟胺的組合來治療多發性硬化症
GB2525530B (en) Treatment of hard surfaces
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment